CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
Kelonia Therapeutics, Inc.
AVM Biotechnology Inc
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Georgetown University
Acerta Pharma BV
National Institutes of Health Clinical Center (CC)
Assistance Publique - Hôpitaux de Paris
Cellectar Biosciences, Inc.
Center for International Blood and Marrow Transplant Research
Azienda Ospedaliero-Universitaria di Parma
Azienda Ospedaliero-Universitaria di Parma
Baylor College of Medicine
Children's Oncology Group
Mayo Clinic
Cancer Research UK
University Health Network, Toronto
Pierre Fabre Medicament
Pierre Fabre Medicament
University of Heidelberg Medical Center
OHSU Knight Cancer Institute
M.D. Anderson Cancer Center
Emory University
Center for International Blood and Marrow Transplant Research
University of Michigan Rogel Cancer Center
Mayo Clinic
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
Pfizer
AbbVie
Cancer Research UK
Cancer Research UK
Cancer Research UK
Cancer Research UK
UNC Lineberger Comprehensive Cancer Center
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Dana-Farber Cancer Institute
Baylor College of Medicine
Baylor College of Medicine
Barbara Ann Karmanos Cancer Institute
UNC Lineberger Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
UNC Lineberger Comprehensive Cancer Center
Novartis
Columbia University
Viracta Therapeutics, Inc.
University of Liverpool